Stroke Volume Variations and Pulse Pressure Variations Undergoing Artificial Pneumothorax Surgery
Launched by CHINESE PLA GENERAL HOSPITAL · Dec 8, 2022
Trial Information
Current as of February 05, 2025
Completed
Keywords
ClinConnect Summary
Backgroud: This study aims to evaluate the ability of stroke volume variation (SVV) and pulse pressure variation (PPV) to predict fluid responsiveness in mechanically ventilated participants with artificial Pneumothorax during esophageal surgery.
Methods: 40 participants, diagnosed with esophageal cancer, undergoing thoracoscopic radical resection of esophageal cancer were studied. All the participants used Vigileo/FloTrac system for analysis. Haemodynamic data such as MAP, HR, SV, SVI, CO, CI, SVV, PPV were recorded before and after volume expansion (VE). Fluid responsiveness was defined ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Must be arranged for thoracoscopic surgical treatment of esophageal cancer Must be mechanically ventilated with artificial Pneumothorax during the operation Must be normal in Allen test.
- Exclusion Criteria:
- • Hypertension Coronary heart disease Arrhythmia Left ventricle ejection fractions \< 50% (EF\<50%) Pulmonary hypertension Congenital cardiovascular malformation Peripheral vascular disease Long-term history of oral vasoactive drugs
Trial Officials
Mi Weidong, Doctor
Study Chair
Chinese PLA General Hospital
About Chinese Pla General Hospital
The Chinese PLA General Hospital, a prominent military medical institution in Beijing, serves as a leading sponsor for clinical trials, focusing on advancing healthcare through innovative research and development. Renowned for its comprehensive medical services and cutting-edge research capabilities, the hospital is committed to improving patient outcomes through rigorous scientific investigation and collaboration with various stakeholders in the healthcare sector. With a multidisciplinary approach and a strong emphasis on evidence-based practices, the Chinese PLA General Hospital aims to contribute significantly to the global medical community by facilitating the development of safe and effective therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials